Free shipping on all orders over $ 500

TMC310911

Cat. No. M27589
TMC310911 Structure
Synonym:

ASC-09

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC50 values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong antiviral activity.

Chemical Information
Molecular Weight 755.99
Formula C38H53N5O7S2
CAS Number 1000287-05-7
Form Solid
Solubility (25°C) DMSO 100 mg/mL (ultrasonic)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Soodeh Mahdian, et al. J Diabetes Metab Disord. Drυg repurposing using computational methods to identify therapeutic options for COVID-19

[2] Iruthayaraj Ancy, et al. J Biomol Struct Dyn. Possibility of HIV-1 protease inhibitors-clinical trial drυgs as repurposed drυgs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study

[3] Richard M W Hoetelmans, et al. J Acquir Immune Defic Syndr. Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies

[4] Hans-Jürgen Stellbrink, et al. J Acquir Immune Defic Syndr. Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients

[5] Inge Dierynck, et al. Antimicrob Agents Chemother. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors

Related HIV Protease Products
Arg-Val-(Nle-p-nitro)-Phe-Glu-Ala-Nle-NH2

Arg-Val-(Nle-p-nitro)-Phe-Glu-Ala-Nle-NH2 is a fluorogenic substrate of HIV-1 protease.

Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2

Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2 is a substrato peptídico of HIV-1 protease.

HIV-1, HIV-2 Protease Substrate

HIV-1, HIV-2 Protease Substrate is the substrate of HIV-1, HIV-2 protease.

HIV Protease Substrate IV

HIV Protease Substrate IV is a substrate of HIV protease.

Herpes virus inhibitor 2

Herpes virus inhibitor 2 is a herpes virus inhibitor and disrupts herpes virus ribonucleotide reductase quaternary structure.

  Catalog
Abmole Inhibitor Catalog




Keywords: TMC310911, ASC-09 supplier, HIV Protease, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.